Sector News

Bayer sees IPO cash as war chest for new consumer deals

November 24, 2014
Life sciences
Once Bayer raises the billions it anticipates from an IPO of its plastics business, it plans to pay off debt. But after that? Expect some OTC acquisitions, the company’s CEO says.
 
Bayer is spinning off plastics in a move away from its chemical roots, preferring to focus on its fast-growing pharma unit and its assets in an expanding consumer health space. The proceeds will help Bayer march toward its goal of becoming the largest OTC player in the world, chief exec Marijn Dekkers told the Financial Times, tabbing the consumer health market as an “obvious consolidation play.”
 
To see that, one just needs to look at the array of different suppliers to the shelves of pharmacy giants like Boots in the U.K., he points out. “That means that nobody has really optimized their relationship with Boots yet,” he told the paper.
 
And Bayer wants to be at the front of the pack. It’s shown as much so far this year, grabbing China’s Dihon Pharmaceuticals before shelling out $14.2 billion for Merck’s consumer unit.
 
“We believe that critical mass is important,” he told the Times. “You need to be a large player there. If you don’t participate in consolidation you fall behind, and that is competitively dangerous.”
 
Other drugmakers have received that memo, too. Fellow pharma giants GlaxoSmithKline and Novartis this April agreed to team up on a consumer health joint venture, which will take the top spot in the OTC market after the deal closes next year. And then there’s Perrigo, which will vault into the top 5 after inking a $4.5 billion deal for Belgium’s Omega Pharma last month, the FT notes.
 
As Bayer looks to snap up future OTC targets, it might have a slew of additional competitors to fend off, too. Sanofi, for one, has actively grown its consumer health business since buying out Tennessee’s Chattem, and it was rumored to be a potential bidder for Omega–along with Bayer itself. Reckitt Benckiser, which entered a two-horse race for the Merck unit this year before ceding it to the German company, plans to spin off its underperforming pharma unit to double down on OTC, too.
 
By Carly Helfand
 

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”